Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Ryan Mak who wrote (83902)	2/22/2000 11:03:00 AM
From: Jenna	Read Replies (2) \| Respond to of 120523

Not completely.. --->TEVA<---- had a blast, ABSC trickled to an easy sell and I had about 4 others that wound down after a wild wild up blast. I did mention TEVA was my favorite. I have armloads of work for tonight. I'm intending to get ESP set up in my computer together with E/signal and Metastock Professional for tomorrow. We had a great time at the expo and I'll be back in New York in March for the Pristine Seminar. There were just too many people there to see everyone. ARDM, CGRM, MRVC,RNBO, QGENF were fine today as well. Teva Pharmaceutical Industries Ltd. to Launch Generic Equivalent of Voltaren XR Immediately JERUSALEM--(BUSINESS WIRE)--Feb. 22, 2000--Teva Pharmaceutical Industries Ltd, (NASDAQ: TEVA - news) announced that it will immediately launch Diclofenac Extended Release (once-a-day) in its 100 mg dosage form. Diclofenac Extended Release is the generic equivalent of Novartis Voltaren XR, which is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Branded sales of Voltaren XR in the United States for the twelve months ended December 31st, 1999 were $98 million. Sunday February 20, 4:33 am Eastern Time Teva shares surge early on drug approval JERUSALEM, Feb 20 (Reuters) - Teva Pharmaceuticals stocks gained more than 4 percent in early trade on Sunday after the company received final U.S. approval to market a generic treatment for osteoarthritis and rheumatoid arthritis

To: Ryan Mak who wrote (83902)	2/22/2000 11:09:00 AM
From: Rick Buskey	Respond to of 120523

Ryan----buy the biotechs when they are down----short term profit taking-------long term holds for us.